Arynta Solution
Product Images NDC 24338-019

Product Visual Gallery

This gallery contains 47 technical images submitted to the FDA as part of the official labeling for Arynta (NDC 24338-019). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Azurity Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure-1 (Figure 1)

This is a table showing specific populations and their PK fold change along with 90% confidence intervals for a specific medication. The populations considered include different age groups and levels of renal impairment. The table outlines the fold change in Cmax (maximum concentration) and AUC (area under the curve) relative to a reference group.*

FDA Label Image

Figure-2 (Figure 2)

This is a comparison table displaying the PK Fold Change and 90% confidence intervals for the drugs Guanfacine, Venlafaxine, and Omeprazole. The table includes data on Cmax and AUC with corresponding values at different time points. The text indicates that the change relative to the reference drug is 2.0.*

FDA Label Image

Figure-3 (Figure 3)

This text provides a list of interacting drugs including Guanfacine and Venlafaxine with various CYP enzyme substrates such as CYP1A2, CYP2D6, CYP2C19, and CYP3A. It also mentions pharmacokinetic parameters like Cmax and AUC, along with fold change and 90% confidence intervals for these interactions. The text indicates changes relative to a reference value of 2.0.*

FDA Label Image

Figure-4 (Figure 4)

LS Mean (SE) SKAMP Deportment Scores data is shown graphically for Placebo and Lisdexamfetamine dimesylate over a 15 to 13 hours post-dose period. The scores appear to decrease over time from 20 to 0.0 for both treatments.*

FDA Label Image

Figure-5 (Figure 5)

FDA Label Image

Figure-6 (Figure 6)

This text provides LS Mean (SE) PERMP Total Scores for placebo and Lisdexamfetamine dimesylate at different time points post-dose in hours. The scores range from 250 to 330 with incremental values. This data can be useful for evaluating the effects of Lisdexamfetamine dimesylate on PERMP Total Scores compared to placebo over time.*

FDA Label Image

Figure-8 (Figure 7)

This description seems to include a comparison between Lisdexamfetamine dimesylate and Placebo. It shows percentage (%) data related to fatigue and productivity over time (days after randomization), possibly from a study or experiment.*

FDA Label Image

Figure-8 (Figure 8)

FDA Label Image

Ifu Figure-a (Ifu Figure A)

This text appears to be a description of an oral dosing syringe. It includes components such as a plunger, barrel, and a white end adapter. The syringe likely has a wrap feature based on the text provided.*

FDA Label Image

Ifu Figure-b (Ifu Figure B)

FDA Label Image

Ifu Figure-c (Ifu Figure C)

FDA Label Image

Ifu Figure-d (Ifu Figure D)

This appears to be a simple description mentioning "Figure D" and "bottle neck". It can be part of a manual, document, or presentation where a visual aid labeled Figure D is showing a bottle neck or detailing a process related to it.*

FDA Label Image

Ifu Figure-e (Ifu Figure E)

FDA Label Image

Ifu Figure-f (Ifu Figure F)

FDA Label Image

Ifu Figure-g (Ifu Figure G)

FDA Label Image

Ifu Figure-h (Ifu Figure H)

Measure the white end of the plunger.*

FDA Label Image

Ifu-figure-hdpe-d (Ifu Figure Hdpe D)

FDA Label Image

Ifu-figure-hdpe-e (Ifu Figure Hdpe E)

FDA Label Image

Ifu-figure-hdpe-f (Ifu Figure Hdpe F)

FDA Label Image

Ifu-figure-hdpe-g (Ifu Figure Hdpe G)

FDA Label Image

Ifu-figure-hdpe-h (Ifu Figure Hdpe H)

FDA Label Image

Ifu-figure-hdpe-i (Ifu Figure Hdpe I)

FDA Label Image

Ifu-figure-hdpe-j (Ifu Figure Hdpe J)

FDA Label Image

Ifu-figure-hdpe-k (Ifu Figure Hdpe K)

This text provides a warning stating "do not touch plunger when removing syringe". It is important to take precaution when handling syringes to prevent any accidents or damage.*

FDA Label Image

Ifu-figure-hdpe-l (Ifu Figure Hdpe L)

FDA Label Image

Ifu-figure-hdpe-m (Ifu Figure Hdpe M)

FDA Label Image

Ifu-figure-hdpe-n (Ifu Figure Hdpe N)

FDA Label Image

Ifu-figure-hdpe-o (Ifu Figure Hdpe O)

FDA Label Image

Ifu-figure-hdpe-p (Ifu Figure Hdpe P)

FDA Label Image

Ifu Figure-i (Ifu Figure I)

FDA Label Image

Ifu Figure-j (Ifu Figure J)

This text seems to provide a cautionary note to "donot touch plunger when removing syringe." It warns the user against touching the plunger during this process to ensure safety.*

FDA Label Image

Ifu Figure-k (Ifu Figure K)

FDA Label Image

Ifu Figure-l (Ifu Figure L)

FDA Label Image

Ifu Figure-m (Ifu Figure M)

FDA Label Image

Ifu Figure-n (Ifu Figure N)

FDA Label Image

Ifu Figure-o (Ifu Figure O)

FDA Label Image

100ml-carton (Lisdex 10mg 100ml Carton)

This text provides detailed information about Arynta oral solution containing lisdexamfetamine dimesylate. The medication is available in a 100 mL bottle with a concentration of 10 mg/mL. It includes storage instructions, dosage recommendations, and warnings to keep out of children's reach. The product should be discarded 30 days after opening. Each pack includes a bottle of Arynta, an oral dosing syringe, a bottle adapter, prescribing information, medication guide, and instructions for use. The product is manufactured for Azurity Pharmaceuticals, Inc. in Woburn, MA.*

FDA Label Image

100ml-label (Lisdex 10mg 100ml Label)

This is a description of a medication identified as Arynta (lisdexamfetamine dimesylate) oral solution with a concentration of 10 mg/mL. This medication is for oral use only and each mL contains 10 mg of lisdexamfetamine dimesylate. It is accompanied by a medication guide that should be given to each patient. The recommended dosage and storage instructions are provided, including details on temperature conditions. Additionally, there are warnings to keep the medication out of the reach of children and to discard any remaining solution after 30 days of first opening the bottle. The manufacturer of this medication is Azurity Pharmaceuticals, Inc., based in Woburn, MA, USA.*

FDA Label Image

Lesidex-10mg-120ml-carton (Lisdex 10mg 120ml Carton)

This is a detailed prescription information for Arynta oral solution, containing lisdexamfetamine dimesylate, with a concentration of 10 mg/mL. It includes dosage recommendations, storage instructions, and precautions to keep the medication away from children. The text also mentions the NDC number, manufacturer details, and items included in the packaging like a dosing syringe and bottle adapter. The medication guide is to be dispensed with each prescription and is available on the manufacturer's website.*

FDA Label Image

Lesidex-10mg-120ml-label (Lisdex 10mg 120ml Label)

This text is a label from a medication bottle containing lisdexamfetamine dimesylate oral solution with a concentration of 10 mg/mL. It provides important information for pharmacists and patients, including dosage recommendations, storage instructions, manufacturer details, and expiration details. The medication guide should be dispensed to each patient, and the medication should be kept out of reach of children. The bottle should be stored at room temperature and tightly closed. Additionally, any remaining medication should be discarded after 30 days of opening the bottle.*

FDA Label Image

30ml-carton (Lisdex 10mg 30ml Carton)

This text is a prescription label for Arynta, an oral solution containing lisdexamfetamine dimesylate at a concentration of 10 mg/mL. The recommended dosage and storage instructions are provided, including keeping the medication at 20°C to 25°C and discarding any remaining solution after 30 days of opening the bottle. The label instructs pharmacists to dispense a Medication Guide to each patient and lists the components of the packaging. The text also indicates that variable data will be printed in the provided panel.*

FDA Label Image

Lesidex-10mg-30ml-label (Lisdex 10mg 30ml Label)

This text provides information about a medication named Arynta, specifically an oral solution containing lisdexamfetamine dimesylate at a concentration of 10 mg/mL. It includes details such as recommended dosage, storage instructions, and a warning to keep the medication out of reach of children. The text also mentions the manufacturer, Azurity Pharmaceuticals, Inc., and advises to discard any remaining medication 30 days after opening the bottle. Additionally, it encourages pharmacists to provide a Medication Guide to each patient and provides a website for further information.*

FDA Label Image

Lesidex-10mg-60ml-carton (Lisdex 10mg 60ml Carton)

The text seems to be a promotional material for a medication called Arynta, which is an oral solution containing lisdexamfetamine dimesylate at a concentration of 10 mg/mL. The medication is for oral use only and is dispensed with a medication guide for each patient. It provides details on dosage recommendations, storage instructions, and precautions to keep the medication out of the reach of children. The package includes a 60 mL bottle of Arynta, an oral dosing syringe, a bottle adapter, prescribing information, and instructions for use. The medication is manufactured by Azurity Pharmaceuticals, Inc. in Woburn, MA.*

FDA Label Image

Lesidex-10mg-60ml-label (Lisdex 10mg 60ml Label)

This text is a description of a medication called Arynta, which is an oral solution containing lisdexamfetamine dimesylate. Each milliliter of the solution contains 10 mg of lisdexamfetamine dimesylate. The recommended dosage should be followed as per the prescribing information. It is important to keep this medication out of reach of children and store it at the recommended temperature range. The medication guide should be dispensed to each patient and is also available at arynta.com. Additionally, the container should be tightly closed, and any remaining solution should be discarded 30 days after opening the bottle. The medication is manufactured for Azurity Pharmaceuticals, Inc. in Woburn, MA, USA.*

FDA Label Image

Lesidex-10mg-90ml-carton (Lisdex 10mg 90ml Carton)

This is a medication information for Arynta containing lisdexamfetamine dimesylate in oral solution form. Each milliliter contains 10 mg of isdexamfetamine dimesylate, which is equivalent to 5.8 mg of sdexamfetamine. The recommended dosage should be followed as per the prescribing information. It is advised to store the medication at 20°C to 25°C and keep it out of reach of children. The medication should be dispensed with the enclosed Medication Guide to each patient. The carton includes a bottle of Arynta 90 mL, an oral dosing syringe, a bottle adapter, Prescribing Information, Medication Guide, and Instructions for Use. After opening, the medication should be discarded after 30 days.*

FDA Label Image

Lesidex-10mg-90ml-label (Lisdex 10mg 90ml Label)

This text contains important information about ARYNTA (lisdexamfetamine dimesylate) oral solution, which is available at a concentration of 10 mg/mL for oral use. It includes instructions for pharmacists to dispense the enclosed Medication Guide to each patient and provides storage recommendations. Additionally, it states the dosage of the medication and highlights the importance of keeping it out of the reach of children. The product should be stored between 20°C to 25°C with excursions permitted to 15°C to 30°C. It advises discarding any remaining ARYNTA 30 days after first opening the bottle. The medication is manufactured by Azurity Pharmaceuticals, Inc.*

FDA Label Image

Lisdex Structure (Lisdex Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.